Introduction
============

Combined hepatocellular cholangiocarcinoma (cHCC-CC), a rare and unique form of primary liver malignancy, was first described in 1949 by Allen and Lisa ([@b1-ol-0-0-7882]), and accounts for 0.4--14.2% of primary liver malignancies ([@b2-ol-0-0-7882],[@b3-ol-0-0-7882]). The World Health Organization classification defines cHCC-CC as a tumor containing unequivocal HCC and CC components; the condition is distinguished from separate HCC and intrahepatic CC (ICC) arising in the same liver ([@b4-ol-0-0-7882]).

The prognosis of patients with cHCC-CC undergoing liver resection has been reported to be poor. The 5-year overall survival (OS) rate was reported to be 37.2%, and the 5-year disease free survival rate was 10.7% ([@b5-ol-0-0-7882]); therefore, it is necessary to identify the prognostic factors of patients diagnosed with cHCC-CC who underwent surgical resection.

Due to its low prevalence, the prognostic factors of cHCC-CC remain unclear. The well-known Tumor-Node-Metastasis (TNM) staging system for cHCC-CC remains controversial and poorly understood ([@b6-ol-0-0-7882]). Whether common prognostic factors (particularly lymph nodal metastasis, which has been most frequently revealed to be associated with the prognosis of various solid tumors, including HCC and ICC) ([@b5-ol-0-0-7882],[@b7-ol-0-0-7882]) leads to a poorer prognosis in patients with HCC-CC is also controversial ([@b8-ol-0-0-7882]). Certain previous studies demonstrated that lymph node metastasis was a significant prognostic factor in patients with cHCC-CC ([@b5-ol-0-0-7882]), while in other reports ([@b6-ol-0-0-7882]), lymphatic metastasis failed to represent a significant prognostic factor. Thus, novel prognostic markers are required to predict the prognosis of patients with cHCC-CC.

Inflammation serves an important role in the development and progression of numerous malignancies by participating in the neoplastic process, proliferation and migration ([@b9-ol-0-0-7882]). Systemic inflammation is a complex progress, the response to which can be assessed using the neutrophil-to-lymphocyte ratio (NLR) ([@b10-ol-0-0-7882]). Elevated pre-treatment NLR has been confirmed to be associated with poor outcomes in various types of cancer, including non-small cell lung cancer ([@b11-ol-0-0-7882]), gastric cancer ([@b12-ol-0-0-7882]), ovarian cancer ([@b13-ol-0-0-7882]), advanced pancreatic cancer ([@b14-ol-0-0-7882]), hepatocellular carcinoma ([@b15-ol-0-0-7882]--[@b19-ol-0-0-7882]) and cholangiocarcinoma ([@b20-ol-0-0-7882]). However, the utility of the NLR has not been validated in cHCC-CC.

The present study hypothesized that the NLR may be a practical predictor of the inflammatory process, and investigated the association between inflammation and the prognosis of patients with cHCC-CC. Therefore, the present retrospective study evaluated the association between the NLR and prognosis in patients with cHCC-CC who underwent surgical resection.

Patients and methods
====================

### Patient cohort

A total of 59 patients who underwent surgical resection and were histologically diagnosed with cHCC-CC between January 2000 and October 2014 at the Department of Hepatobiliary and Pancreatic Surgery (Sun Yat-sen University Cancer Center, Guangzhou, China) were retrospectively recruited. Exclusion criteria were as follows: i) other treatments, including transarterial chemoembolization, radiofrequency treatment and liver transplantation for patients with HCC before surgical resection; ii) inadequate renal function (serum creatinine level and blood urea nitrogen level higher than the upper limits of normal); iii) severe coagulopathy (prothrombin activity \<40% or platelet count \<40,000/mm^3^); iv) Child-Pugh C liver function or evidence of hepatocellular decompensation, including refractory ascites, esophageal or gastric variceal bleeding, and hepatic encephalopathy; v) obstructive jaundice; vi) other concurrent primary tumors; vii) pathological confirmed subtype of cHCC-CC with stem cell features or viii) follow-up period of \<3 months or lost to follow up.

### Clinical data collection

All clinicopathological data were retrieved from medical records at the Department of Hepatobiliary and Pancreatic Surgery of the Sun Yat-sen University Cancer Center. Clinicopathological parameters included histologically confirmed cHCC-CC, age, gender, leukocyte cell count, neutrophil cell count and lymphocyte cell count, levels of hemoglobin, platelets, α-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9), γ-glutamyl transpeptidase (GGT) and hepatitis B surface antigen (HbsAg), tumor size, tumor number, lymph node metastasis, major thrombi, microvascular thrombi, and conventional TNM stage for HCC and ICC, as established by the Union for International Cancer Control and the American Joint Committee on Cancer (AJCC) ([@b21-ol-0-0-7882]) ([Table I](#tI-ol-0-0-7882){ref-type="table"}). The laboratory data were obtained prior to surgical resection. The present study was approved by the Institutional Review Board of the Sun Yat-sen University Cancer Center. Written informed consent was obtained from all patients prior to enrollment in the present study.

### Follow-up

Patients were followed up at least every 2 months during the first year and every 3 months thereafter. Tumor markers, including AFP, CEA and CA19-9 tests, liver ultrasonography, computed tomography and magnetic resonance imaging, were selected as required. OS was defined as the duration (in months) from the date of surgery until cancer-specific mortality or last follow-up. The final follow-up date was August 1, 2015.

### Statistical analysis

The optimal cut-off values for NLR were determined using time-dependent receiver operating curve (ROC) analysis. Time-dependent ROC analysis was performed using R software version 3.2.2 (The R Foundation for Statistical Computing, Vienna, Austria; <http://www.r-project.org>) and the 'survival ROC' package ([@b22-ol-0-0-7882]). The NLR was evaluated by dividing the neutrophil cell counts by the lymphocyte cell counts. The NLR value was categorized into two groups: NLR≤2.75 and NLR\>2.75.

SPSS version 22 (IBM Corp., Armonk, NY, USA) was used to analyze the data. Continuous variables were expressed as the mean ± standard deviation and the range, and were compared between the NLR≤2.75 and NLR\>2.75 groups using Student\'s t-test. The χ^2^ test and Fisher\'s exact test were used to compare categorical variables, which were presented as the number and percentage of patients.

Survival curves for OS were analyzed using the Kaplan-Meier method. Significant differences between groups were identified using the log-rank test. A univariate analysis was performed to assess significant differences in clinicopathological characteristics. A multivariate analysis was performed via Cox regression for variables significant in a univariate analysis, and the associated 95% confidence interval (CI) was determined. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

A total of 59 patients were diagnosed with cHCC-CC between January 2000 and October 2014, and consecutively enrolled in the present retrospective study. The median patient age was 49 years (range, 25--75 years). Among these patients, 43 (72.9%) were male and 16 (27.1%) were female. There were 40 (67.8%) patients in the HCC early-stage group and 19 (32.2%) patients in the HCC advanced-stage group, according to the TNM staging system. Furthermore, according to the ICC TNM staging system, 45 (76.3%) patients were in the early-stage group and 14 (23.7%) patients were in the advanced-stage group at diagnosis.

Among the patients diagnosed with cHCC-CC, 52 were included in the present study for prognostic analysis; the remaining 7 were excluded, as their survival time was \<3 months. The study cohort for the prognostic analysis consisted of 37 (71.2%) males and 15 (28.8%) females, and was prospectively recruited and retrospectively analyzed. The median age of the patients in the prognostic analysis was 50 years (range 27--75 years).

The clinicopathological characteristics of the investigated patients in the prognostic analysis are presented in [Table I](#tI-ol-0-0-7882){ref-type="table"}. A total of 8 patients (15.4%) were older than 60 years, and the majority of the patients (71.2%) were male. Depending on the selected NLR value, patients were divided into two groups: NLR≤2.75 and NLR\>2.75. A total of 41 patients (78.8%) were in the NLR≤2.75 group, whereas 11 patients (21.2%) were in the NLR\>2.75 group. There were no significant differences regarding age, gender, AFP, CA19-9, GGT, HbsAg, tumor number, lymph node metastasis, major thrombi, microvascular thrombi, HCC stage or ICC stage between the two groups; however, tumor size was significantly larger in the NLR\>2.75 group compared with that in the NLR≤2.75 group (log-rank test, P=0.017).

### Association between NLR and tumor stage

The association between NLR and tumor stage, which was the primary determinant of patient prognosis, was evaluated. As presented in [Fig. 1A](#f1-ol-0-0-7882){ref-type="fig"}, the NLR value was compared between the early-stage group (HCC stage I and II) and the advanced-stage group (HCC stage III and IV), according to the TNM staging system. The NLR value was significantly higher in the advanced-stage group compared with that in the early-stage group (3.19±2.34 vs. 2.00±1.17; P=0.001). However, there was no difference in NLR value between the ICC early-stage group and the ICC advanced-stage group according to TNM staging system (2.29±1.87 vs. 1.70±1.08; P=0.301; [Fig. 1B](#f1-ol-0-0-7882){ref-type="fig"}).

### Overall survival according to NLR

The OS rates of the patients in the advanced-stage group were significantly poorer compared with those in the early-stage group, according to the HCC staging system (1-year OS: 74.7 vs. 88.6%; 2-year OS: 40.7 vs. 71.4%; P=0.009; [Fig. 2](#f2-ol-0-0-7882){ref-type="fig"}). However, the difference in OS rates between the early-stage and advanced-stage patients in the ICC stage system were not significant (1-year OS: 87.7 vs. 66.2%; 2-year OS: 73.8 vs. 46.2%; P=0.169; [Fig. 3](#f3-ol-0-0-7882){ref-type="fig"}).

The OS rates of the patients with NLR≥2.75 were significantly lower compared with those of the patients with NLR≤2.75 (1-year OS: 63.6 vs. 89.9%; 2-year OS: 24.2 vs. 72.1%; P=0.004). The median survival time was longer in the NLR≤2.75 group compared with that in the NLR\>2.75 group (83.6 vs. 15 months; P=0.004) ([Fig. 4](#f4-ol-0-0-7882){ref-type="fig"}).

### Prognostic significance of NLR in patients with cHCC-CC

The clinicopathological parameters were included in the univariate and multivariate analyses to further investigate the prognostic factors of patients with cHCC-CC. As presented in [Table II](#tII-ol-0-0-7882){ref-type="table"}, tumor size, HCC TNM stage and NLR were significant factors associated with OS in the univariate analysis. The significant predictors were then utilized for multivariate proportional hazard regression analysis. The multiple analysis results revealed that advanced stage in the HCC TNM staging system \[hazard ratio (HR), 2.527; 95% CI, 1.088--5.872; P=0.031\] and NLR\>2.75 (HR, 2.990; 95% CI, 1.198--7.462; P=0.019) were independent prognostic factors of poor OS in cHCC-CC ([Table II](#tII-ol-0-0-7882){ref-type="table"}).

Discussion
==========

cHCC-CC is a mixed carcinoma that is composed of two distinct tumor elements in which HCC and CC intimately coexist ([@b4-ol-0-0-7882]). The present study confirmed the prognostic value of NLR in a cohort of patients with cHCC-CC.

Inflammatory processes have been identified to serve a role in tumor progression ([@b9-ol-0-0-7882]). Growth and survival factors released from inflammatory cells can stimulate tumor formation, progression, angiogenesis, invasion and metastasis ([@b23-ol-0-0-7882]--[@b25-ol-0-0-7882]). The paradoxical roles of adaptive (lymphocyte immune cells) and innate leukocytes (circulating neutrophils) in inflammatory processes act as crucial opposing regulators in cancer occurrence ([@b26-ol-0-0-7882]). Immune cell-like neutrophils have been associated with increased angiogenesis and/or a poor prognosis, which is in part explained by the upregulation of cyclooxygenase-2 or the suppression of an antitumor adaptive immune response ([@b27-ol-0-0-7882]--[@b29-ol-0-0-7882]). However, lymphocytes have been essential components in tumor defense via killing tumor cells and inhibiting cell proliferation or migration ([@b9-ol-0-0-7882],[@b30-ol-0-0-7882]). Additionally, certain previous studies suggested that adaptive immune cells, including B-lymphocytes, cluster of differentiation (CD)8^+^ cytotoxic T-lymphocytes and CD4^+^ helper T-lymphocytes, served important roles in the modulation of cancer development via the lysis of tumor cells ([@b26-ol-0-0-7882],[@b31-ol-0-0-7882]).

Inflammation is a complex process that may be reflected by NLR, a practical biomarker. The present study demonstrated a substantial difference in NLR between early- and advanced-stage HCC (P=0.001); however, there were no significant differences in NLR values between early and advanced ICC stage according to the TNM staging system (P=0.301). cHCC-CC has been included in the ICC section of the TNM staging system in accordance with the AJCC manual ([@b21-ol-0-0-7882]); however, a study with a larger cohort suggested that the HCC TNM staging system provided an better prognostic stratification for patients with cHCC-CC ([@b6-ol-0-0-7882]). Similarly, in the present study, the OS rates of patients with advanced HCC stage were significantly lower compared with those of patients with early stage disease, according to the TNM staging system. However, there were no differences in OS between the early and advanced ICC stages, according to the TNM staging system (P=0.301). Furthermore, a recent study revealed that the NLR value exhibited a linear association with cancer progression staging ([@b17-ol-0-0-7882]). This may partly explain the difference in NLR value between early- and advanced-stage HCC present in the TNM staging system but not the ICC TNM staging system in the present study.

Increasing evidence has suggested that NLR is a prognostic factor for OS in various types of cancer. Various cut-off values have been used to describe the association between NLR and survival in these cancer types ([@b32-ol-0-0-7882],[@b33-ol-0-0-7882]). In the present study, a time-dependent ROC was performed to determine the optimal cut-off points for NLR. According to this, the present study demonstrated that patients could be divided into two groups (NLR\>2.75 and NLR≤2.75). Upon univariate and multivariate analyses, the present study confirmed that NLR was an independent prognostic factor. In contrast with the present study, a previous study revealed that an NLR value of \>2 did not independently predict poorer overall survival in patients with cHCC-CC ([@b34-ol-0-0-7882]). This discrepancy may be due to differences in the assays using NLR. The previous study selected the median value as a cut-off point, whereas the present study used a time-dependent ROC curve to select a high-sensitivity value cut-off point for NLR.

There are certain limitations to the present study. Firstly, the total number of recruited patients was relatively small. Secondly, it was a retrospective study and was thus susceptible to bias in data selection and analysis. Other inflammatory markers, including C-reactive protein or procalcitonin, which have been demonstrated to be independent prognostic factors in patients with HCC ([@b17-ol-0-0-7882]) and ICC ([@b35-ol-0-0-7882]), are not routinely evaluated at Sun Yat-sen University. Finally, the present study did not evaluate NLR following surgery, and further investigation is required to determine whether this was associated with OS.

Despite these limitations, the present study suggested that pre-treatment NLR may be associated with OS in patients diagnosed with cHCC-CC and that analysis of the NLR should be introduced in clinical practice. Further prospective studies are required to evaluate cut-off values and confirm the results of the present study.
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![Association between NLR and the TNM staging system. (A) The level of NLR tended to increase with progressing tumor stage according to the hepatocellular carcinoma TNM staging system (P=0.001). (B) There was no significant difference in NLR between the early and advanced stages, according to the intrahepatic cholangiocarcinoma TNM staging system (P=0.301). NLR, neutrophil-to-lymphocyte ratio; TNM, Tumor-Node-Metastasis.](ol-15-04-4262-g00){#f1-ol-0-0-7882}

![Kaplan-Meier curves revealing overall survival in patients who underwent surgical resection according to HCC Tumor-Node-Metastasis stage at diagnosis. Patients in the advanced-stage group exhibited significantly poorer overall survival rates compared with those in the early-stage group according to the HCC staging system (P=0.009). HCC, hepatocellular carcinoma.](ol-15-04-4262-g01){#f2-ol-0-0-7882}

![Kaplan-Meier curves revealing overall survival in patients who underwent surgical resection according to the ICC Tumor-Node-Metastasis stage at diagnosis. The difference between the early- and advanced-stage groups was not significant (P=0.169). ICC, intrahepatic cholangiocarcinoma.](ol-15-04-4262-g02){#f3-ol-0-0-7882}

![Kaplan-Meier curves revealing overall survival in patients according to NLR value at diagnosis. Patients with NLR≥2.75 exhibited significantly poorer overall survival rates compared with those with NLR≤2.75 (P=0.004). NLR, neutrophil-to-lymphocyte ratio.](ol-15-04-4262-g03){#f4-ol-0-0-7882}

###### 

Clinicopathological factors in NLR≤2.75 (n=41) and NLR\>2.75 (n=11) groups at diagnosis.

  Variables                                                       NLR≤2.75, n   NLR≤2.75, n   P-value
  --------------------------------------------------------------- ------------- ------------- ---------
  Age, years                                                                                  
    ≤60                                                           35              9           
    \>60                                                            6             2           0.856
  Gender                                                                                      
    Female                                                        11              4           
    Male                                                          30              7           0.709
  AFP, ng/ml                                                                                  
    ≤25                                                           16              4           
    \>25                                                          25              7           0.851
  CA19-9, U/ml                                                                                
    ≤35                                                           27              9           
    \>35                                                          14              2           0.468
  GGT, U/l                                                                                    
    ≤50                                                           21              2           
    \>50                                                          20              9           0.086
  HbsAg                                                                                       
    Negative                                                        5             1           
    Positive                                                      36            10            0.806
  Tumor size, cm                                                                              
    \<5                                                           24              2           
    ≥5                                                            17              9           0.017
  Tumor number                                                                                
    Solitary                                                      11              3           
    Multiple                                                      30              8           0.724
  Lymph node metastasis                                                                       
    Negative                                                      37              8           
    Positive                                                        4             3           0.154
  Major thrombi                                                                               
    Negative                                                      37            11            
    Positive                                                        4             0           0.567
  Microvascular thrombi                                                                       
    Negative                                                      35              9           
    Positive                                                        6             2           0.856
  HCC stage                                                                                   
    Early stage^[a](#tfn1-ol-0-0-7882){ref-type="table-fn"}^      30              5           
    Advanced stage^[b](#tfn2-ol-0-0-7882){ref-type="table-fn"}^   11              6           0.145
  ICC stage                                                                                   
    Early stage                                                   32              7           
    Advanced stage                                                  9             4           0.435

Stage I and II

stage III and IV. AFP, α-fetoprotein; CA19-9, carbohydrate antigen 19-9; GGT, γ-glutamyl transpeptidase; HbsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma.

###### 

Univariate and multivariate analyses of factors associated with overall survival in 52 patients with combined hepatocellular-cholangiocarcinoma.

                                                                               Univariate              Multivariate                          
  --------------------------------------------------------------- ----- ------ ----------------------- -------------- ---------------------- -------
  Age, years                                                                                                                                 
    ≤60                                                           44    84.6   Reference value                                               
    \>60                                                            8   15.4   0.716 (0.212--2.417)    0.590                                 
  Gender                                                                                                                                     
    Female                                                        15    28.8   Reference value                                               
    Male                                                          37    71.2   1.487 (0.551--4.015)    0.434                                 
  AFP, ng/ml                                                                                                                                 
    ≤25                                                           20    38.5   Reference value                                               
    \>25                                                          32    61.5   1.296 (0.546--3.077)    0.556                                 
  CA19-9, U/ml                                                                                                                               
    ≤35                                                           36    69.2   Reference value                                               
    \>35                                                          16    30.8   1.127 (0.477--2.664)    0.785                                 
  GGT, U/l                                                                                                                                   
    ≤50                                                           23    44.2   Reference value                                               
    \>50                                                          29    55.8   1.788 (0.756--4.229)    0.186                                 
  HbsAg                                                                                                                                      
    Negative                                                        6   11.5   Reference value                                               
    Positive                                                      46    88.5   3.510 (0.470--26.239)   0.221                                 
  Tumor size, cm                                                                                                                             
    \<5                                                           26    50.0   Reference value                                               
    ≥5                                                            26    50.0   3.475 (1.411--8.562)    0.007          1.113 (0.959--1.291)   0.159
  Tumor number                                                                                                                               
    Solitary                                                      14    26.9   Reference value                                               
    Multiple                                                      38    73.1   0.955 (0.375--2.429)    0.923                                 
  Lymph node metastasis                                                                                                                      
    Negative                                                      45    26.5   Reference value                                               
    Positive                                                        7   13.5   3.036 (0.992--9.292)    0.052                                 
  Major thrombus                                                                                                                             
    Negative                                                      48    92.3   Reference value                                               
    Positive                                                        4   7.7    3.121 (0.912--10.684)   0.070                                 
  Microvascular thrombus                                                                                                                     
    Negative                                                      44    84.6   Reference value                                               
    Positive                                                        8   15.4   1.676 (0.556--5.054)    0.305                                 
  HCC stage                                                                                                                                  
    Early stage^[a](#tfn3-ol-0-0-7882){ref-type="table-fn"}^      35    67.3   Reference value                                               
    Advanced stage^[b](#tfn4-ol-0-0-7882){ref-type="table-fn"}^   17    32.7   2.882 (1.258--6.607)    0.012          2.527 (1.088--5.872)   0.031
  ICC stage                                                                                                                                  
    Early stage                                                   39    75.0   Reference value                                               
    Advanced stage                                                13    25.0   1.853 (0.758--4.528)    0.176                                 
  NLR                                                                                                                                        
    ≤2.75                                                         41    78.8   Reference value                                               
    \>2.75                                                        11    21.2   3.474 (1.409--8.563)    0.007          2.990 (1.198--7.462)   0.019

Stage I and II

stage III and IV. AFP, α-fetoprotein; CA19-9, carbohydrate antigen 19-9; GGT, γ-glutamyl transpeptidase; HbsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocarcinoma; HR, hazard ratio; CI, confidence interval; NLR, neutrophil-to-lymphocyte ratio; HR, hazard ratio.
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